Table 1.
Baseline characteristics of sub-study participants by randomized group.
| Characteristic | High-Dose Vitamin D3 (n = 50) |
Standard-Dose Vitamin D3 (n = 55) |
|---|---|---|
| Age, median (IQR), y | 54.2 (46.8–65.3) | 55.5 (49.2–64.7) |
| Sex, No. (%) | ||
| Male | 32 (64.0) | 27 (49.1) |
| Female | 18 (36.0) | 28 (50.9) |
| Race, Ethnicity, No. (%) | ||
| White | 38 (76.0) | 43 (78.2) |
| Black | 2 (4.0) | 5 (9.1) |
| Asian | 0 (0) | 0 (0) |
| >1 Race | 0 (0.0) | 1 (1.8) |
| Other | 10 (20.0) | 6 (10.9) |
| ECOG Performance Status, No. (%) | ||
| 0 | 21 (42.0) | 32 (58.2) |
| 1 | 29 (58.0) | 23 (41.8) |
| Primary Tumor Location, No. (%) | ||
| Right Colon | 12 (24.0) | 15 (27.3) |
| Transverse Colon | 3 (6.0) | 7 (12.7) |
| Left Colon, Rectum | 35 (70.0) | 33 (60.0) |
| Primary Tumor Resected, No. (%) | 20 (40.0) | 17 (30.9) |
| No. of Metastatic Sites, mean (SD) | 2.0 (0.93) | 1.9 (0.91) |
| Carcinoembryonic Antigen *, median (IQR), ng/mL | 64.8 (4.5–565.6) | 91.9 (5.5–393.5) |
| Microsatellite Instability Status, No. (%) | ||
| High | 1 (2.0) | 4 (7.3) |
| Stable | 42 (84.0) | 35 (63.6) |
| Unknown | 7 (14.0) | 16 (29.1) |
| KRAS Mutation Status, No. (%) | ||
| Wild Type | 26 (52.0) | 24 (43.6) |
| Mutated | 22 (44.0) | 24 (43.6) |
| Unknown | 2 (4.0) | 7 (12.7) |
| NRAS Mutation Status, No. (%) | ||
| Wild Type | 29 (58.0) | 30 (54.5) |
| Mutated | 0 (0.0) | 2 (3.6) |
| Unknown | 21 (42.0) | 23 (41.8) |
| BRAF V600E Mutation Status, No. (%) | ||
| Wild Type | 31 (62.0) | 30 (54.5) |
| Mutated | 3 (6.0) | 7 (12.7) |
| Unknown | 16 (32.0) | 18 (32.7) |
* Missing for 1 participant.